Item 8.01. Other Events.

Spero Therapeutics, Inc. (the "Company") issued the press releases attached hereto as Exhibits 99.1 and 99.2 on January 3, 2022 and January 4, 2022, respectively, and they are filed and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.




99.1      Press Release titled "Spero Therapeutics Announces FDA Acceptance and
        Priority Review of New Drug Application for Tebipenem HBr for the
        Treatment of Complicated Urinary Tract Infections including
        Pyelonephritis," dated January 3, 2022.

99.2      Press Release titled "Spero Therapeutics Announces Lifting of FDA
        Clinical Trial Hold on SPR720," dated January 4, 2022.

104     Cover Page Interactive Data File (embedded within the Inline XBRL
        document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses